Improved clinical and simplified disease activity index (CDAI, SDAI) scores with rituximab in patients with rheumatoid arthritis (RA) and an inadequate response to TNF inhibitors

被引：0
|
作者：
Smolen, Josef [1 ]
Cividino, Alfred [2 ]
Kavanugh, Arthur [3 ]
Tony, Hans Peter [4 ]
Greenwald, Maria
De Vita, Salvatore [5 ]
Brasington, Richard [6 ]
Aletaha, Daniel [7 ]
White, Anne Marie [8 ]
Hessey, Eva [8 ]
机构：
[1] Med Univ Vienna, Vienna, Austria
[2] McMaster Univ, Hamilton, ON L8S 4L8, Canada
[3] UCSD, La Jolla, CA USA
[4] Univ Klinikum Wurzburg, Wurzburg, Germany
[5] Univ Udine, I-33100 Udine, Italy
[6] Washington Sch Med, St Louis, MO USA
[7] Med Univ Vienna, Vienna, Austria
[8] Roche Prod Ltd, Welwyn Garden City AL7 3AY, Herts, England
来源：
JOURNAL OF RHEUMATOLOGY | 2008年 / 35卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1191 / 1191
页数：1
相关论文
共 50 条
  • [41] Oral glucocorticoids have no impact on the efficacy or safety profile of rituximab in rheumatoid arthitis (RA) patients with inadequate response to TNF inhibitors (REFLEX study).
    Ruderman, E. M.
    Burmester, G. R.
    Durez, P.
    Loveless, J.
    Kvien, T. K.
    Jackson, C.
    Burke, L.
    Cravets, M.
    White, A. M.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S226 - S227
  • [42] Performance of Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) Appears to be Better Than Gold Standard Disease Assessment Score (DAS-28 CRP)
    Dhaon, Pooj A.
    Das, Siddharth K.
    Srivastava, Ragini
    Dhakad, Urmila
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [43] Inhibition of radiographic progression with rituximab is not dependent on clinical efficacy: Results from a study in rheumatoid arthritis patients with an inadequate response to one or more TNF inhibitors (reflex)
    Keystone, E.
    Emery, P.
    Peterfy, C. G.
    Tak, P. P.
    Cohen, S. B.
    Genoveses, M. C.
    Williams, S.
    Hagerty, D.
    Cravetss, M. W.
    Shaw, Tm.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 431 - 432
  • [44] Inhibition of radiographic progression with rituximab is not dependent on clinical efficacy: Results from a study in rheumatoid arthritis patients with an inadequate response to one or more TNF inhibitors (reflex)
    Emery, Paul
    Keystone, Edward
    Peterfy, Charles G.
    Tak, Paul-Peter
    Cohen, Stanley B.
    Genovese, Mark C.
    Williams, Sarah
    Hagerty, David
    Cravets, Matthew W.
    Shaw, Tim M.
    RHEUMATOLOGY, 2008, 47 : II50 - II50
  • [45] Evaluation of Remission Over 1 Year in Patients (pts) with Early Rheumatoid Arthritis (RA) Treated with Abatacept (ABA) Plus Methotrexate, According to Simplified Disease Activity Index (SDAI)
    Smolen, Josef
    Wollenhaupt, J.
    Gomez-Reino, Juan J.
    Grassi, Walter
    Le Bars, Manuela
    Gaillez, Corine
    Poncet, Coralie
    Elegbe, Ayanbola
    Westhovens, Rene
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S862 - S862
  • [46] Clinical Disease Activity Index (CDAI) is a valid instrument for assessing disease activity amongst oriental early rheumatoid arthritis (ERA) patients.
    Lian, Tsui Y.
    Koh, Ee T.
    Kong, Kok O.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S377 - S378
  • [47] Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study
    Gottenberg, Jacques-Eric
    More, Jacques
    Perrodeau, Elodie
    Bardin, Thomas
    Combe, Bernard
    Dougados, Maxime
    Flipo, Rene-Marc
    Saraux, Alain
    Schaeverbeke, Thierry
    Sibilia, Jean
    Soubrier, Martin
    Vittecoq, Olivier
    Baron, Gabriel
    Constantin, Arnaud
    Ravaud, Philippe
    Mariette, Xavier
    BMJ-BRITISH MEDICAL JOURNAL, 2019, 364
  • [48] Test-retest reliability of the Disease Activity Score 28 CRP (DAS28-CRP), the Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI) in rheumatoid arthritis when based on patient self-assessment of tender and swollen joints
    Heegaard, Cecilie
    Dreyer, Lene
    Egsmose, Charlotte
    Madsen, Ole Rintek
    CLINICAL RHEUMATOLOGY, 2013, 32 (10) : 1493 - 1500
  • [49] Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs
    Narvaez, J.
    Diaz-Torne, C.
    Ruiz, J. M.
    Hernandez, M. V.
    Torrente-Segarra, V.
    Ros, S.
    Rodriguez de la Serna, A.
    Diaz-Lopez, C.
    Sanmarti, R.
    Nolla, J. M.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2011, 29 (06) : 991 - 997
  • [50] Evaluation of clinical responses and demonstration of the sensitivity to change using the clinical and the simplified disease activity index (CDAI, SDAI): Abatacept has a rapid onset of action
    Schiff, M.
    Aletaha, D.
    Bahrt, K. M.
    Boodhoo, T.
    Smolen, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 500 - 500
12345